New Guidance on Managing Weight After Obesity Treatments
Individuals transitioning off obesity medications like Wegovy and Mounjaro are advised to undergo check-ups for at least a year, according to new recommendations from the NHS.
It’s quite common for people to regain much of the weight they lost once they discontinue treatment, as experience suggests. The guidance from NICE, the health assessment body, emphasizes that managing weight should be viewed as a long-term endeavor rather than just a quick solution.
Patients may require additional support and a clear plan to maintain their new weight. This could include healthy eating habits, regular exercise, or simply taking daily walks.
The Scope of Obesity in England
In England, obesity impacts about one in four adults. An estimated 1.5 million individuals in the UK are currently using weight-loss injections, though most are paying out of pocket and therefore won’t receive NHS support as they transition off these treatments.
Wegovy, which contains semaglutide, is available on the NHS but only for high-need patients, typically those with health complications related to obesity and a high BMI, and is limited to a two-year period. In contrast, around 240,000 people are expected to receive Mounjaro (tirzepatide) over the next three years, without a defined duration for its use.
Both medications curb appetite and can result in significant weight loss when used alongside programs promoting healthy lifestyle changes.
Research Findings and Expert Opinions
A clinical trial involving Wegovy showed that participants regained about two-thirds of their weight once they stopped the injections, and similar results have been noted for Mounjaro users.
NICE’s advice encourages patients to cultivate sustainable behavioral habits, utilize self-monitoring tools, and access broader support—from online groups to family and community resources.
Professor Jonathan Benger from NICE stated, “Effective weight management doesn’t conclude when the medication stops or after finishing a behavioral program. We recognize that the period following treatment is vital, and structured support is essential for maintaining the progress made.”
Additionally, Professor Kamila Hawthorn from the Royal College of GPs noted, “There isn’t a one-size-fits-all method for addressing obesity—what is effective for one individual may not work for another. Emphasis should also be placed on prevention to reduce the incidence of obesity and the subsequent need for medical intervention.”
Dealing with obesity often presents challenges in everyday life and increases the risk of severe health issues, including heart disease, type 2 diabetes, and various cancers.
